Regeneron and Sanofi are at it again with their ongoing Dupixent DTC campaign dubbed DU More. The pair of drugmakers rolled out the latest iteration of the campaign on Monday morning, right in time ...

Drug meets primary and all secondary goals in COPD trial Previous peak sales estimate of 13 bln euros was without COPD Drug could be first new COPD treatment in over a decade March 23 (Reuters) - ...

Dupixent is a branded injectable medication doctors prescribe to treat eosinophilic esophagitis (EoE). Doctors usually prescribe 300 milligrams once per week. They mostly prescribe it to adults, but ...

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) for the treatment of pediatric patients (aged one to 11 years) with eosinophilic esophagitis (EoE). This approval, ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected in ...

Dupixent reduced COPD exacerbations by 30% and 34% in two Phase 3 trials. Approximately 300,000 U.S. patients with inadequately controlled COPD can benefit from Dupixent. Missed the rally? Learn ...

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first ...

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first ...

Please provide your email address to receive an email when new articles are posted on . Sustained disease remission occurred in 20% of the study cohort vs. 4% of the placebo group at week 36. 41% of ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Sanofi SNY and partner Regeneron REGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of ...